相关实验视频

Updated: Jul 10, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在淋巴瘤组合疗法中临床PD-1/PD-L1阻塞

Hiroo Katsuya¹, Junji Suzumiya², Shinya Kimura¹

¹Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.

|November 25, 2023

概括

编程细胞死亡蛋白1 (PD-1) /PD-1连接体 (PD-L1) 阻断在淋巴瘤中显示出前景,组合疗法改善了高级经典霍奇金淋巴瘤 (cHL) 的无进展生存率. 对其他淋巴瘤类型的进一步研究正在进行中.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
血液学血液学血液学

背景情况:

针对PD-1/PD-L1的免疫疗法已经改变了先进的固体癌症治疗.
淋巴瘤的临床益处目前仅限于经典的霍奇金淋巴瘤 (cHL) 和原发性中间体B细胞淋巴瘤 (PMBCL).

研究的目的:

审查PD-1/PD-L1阻断结合疗法治疗淋巴瘤的现有情况.
讨论潜在的治疗方法和正在进行的临床试验.

主要方法:

对各种淋巴瘤亚型的组合疗法中研究PD-1/PD-L1阻断的临床试验的综述.
对高级阶段cHL的第三阶段研究的中间结果的分析.

主要成果:

与尼沃卢马布 (nivolumab) 的联合治疗表明,在晚期cHL中,无进展生存率增加.
组合疗法在攻击性B细胞淋巴瘤中显示出令人失望的结果,不包括PMBCL.
目前正在进行的试验探索PD-1/PD-L1阻断与布鲁顿的氨酸激酶抑制剂结合用于具有里希特转换的慢性淋巴细胞白血病 (CLL).

结论:

阻断PD-1/PD-L1的组合疗法对特定的淋巴瘤亚型 (如cHL和T细胞淋巴瘤) 有潜力.
进一步的临床试验至关重要,以确定最优的组合方案,用于前线和复发/耐药的设置在cHL,CLL与里希特转换,T细胞淋巴瘤.

关键词:

在PD-1/PD-L1上进行封锁.结合疗法与免疫疗法联合治疗.淋巴瘤淋巴瘤是什么

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...